Why Novavax Stock Is Volatile This Week
Why Novavax Stock Is Volatile This Week
Novavax Inc (NASDAQ:NVAX) shares dipped 11.2% to $9.60 during Wednesday's session, pulling back following recent strength.
諾瓦瓦克斯醫藥公司（納斯達克：NVAX）的股價在週三的交易中下跌了11.2%，跌至9.60美元，此次回調是在近期強勁表現後的走勢。
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.
在美國報告了首例禽流感死亡病例後，本週疫苗製造商的股價波動較大。此外，最近的一份CDC報告指出急性呼吸疾病活動有所增加。
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of creating vaccines for infectious diseases.
了解一下：作爲一家專注於生物-疫苗開發的公司，諾瓦瓦克斯醫藥有望在應對此類疫情中發揮作用，特別是考慮到其在傳染病疫苗開發方面的歷史。
Read Also: Apple's 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test
另見：蘋果自iTunes推出以來的24年間增長了70,000%，面臨2025年的考驗
While traditional bird flu vaccines from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
雖然賽諾菲安萬特、CSL Seqirus和葛蘭素史克的傳統禽流感疫苗已經被儲備，但它們針對的是舊的H5N1毒株，這爲創新和更新留出了可能的空間。
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has devastated poultry farms and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
諾瓦瓦克斯憑藉其專有的重組納米顆粒疫苗科技，可能被視爲開發下一代禽流感疫苗的競爭者，尤其是在需求增加的情況下。禽流感疫情已經嚴重衝擊了養禽場，並引發了對病毒突變的擔憂，這也突顯了先進生物-疫苗平台的必要性。
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that public risk remains low.
投資者對可能的政府資助或合同以應對疫情的投機，可能會導致諾瓦瓦克斯醫藥股價的波動，儘管CDC表示公衆風險仍然較低。
Read Also: Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
另見：禽流感引發疫苗股票上漲：隨着H5N1疫情加劇，值得關注的ETF
How To Buy NVAX Stock
如何購買NVAX股票
By now you're likely curious about how to participate in the market for Novavax – be it to purchase shares, or even attempt to bet against the company.
到現在，你可能對如何參與諾瓦瓦克斯醫藥的市場感到好奇——無論是購買股票，還是嘗試做空這家公司。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
購買股份通常是通過券商賬戶完成的。你可以在這裏找到可能的交易平台列表。許多平台會允許你購買「碎股」，這意味着你可以購買部分股票而不必買入整份股票。例如，一些股票，如伯克希爾哈撒韋或亞馬遜，擁有一股可能花費數千美元。然而，如果你只想投資其中的一小部分，券商會允許你這樣做。
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
在諾瓦瓦克斯醫藥的情況下，截至出版時，其股價爲9.60美元，100美元將可以買到10.41股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果你想對抗一家公司，過程會更復雜。你需要訪問一個期權交易平台，或者找一個允許你通過借用股票來'開空'股票的券商。有關做空股票的過程可以在這個資源中找到。否則，如果你的券商允許你交易期權，你可以購買一個看跌期權，或者賣出一個行使價高於當前股價的看漲期權——無論哪種方式，都允許你從股價下跌中獲利。
According to data from Benzinga Pro, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
根據Benzinga Pro的數據，NVAX的52周最高價爲23.86美元，52周最低價爲3.53美元。
Image courtesy of Pixabay
圖片來自Pixabay
